Investigators also confirmed racial disparities in COVID-19 hospitalizations and overall deaths early in the pandemic among patients with ESKD.
Investigators report encouraging results from a small observational study testing the effect of preemptive therapeutic plasma exchange and rituximab in kidney transplant recipients whose primary cause of kidney failure was focal segmental glomerulosclerosis.
Autosomal dominant polycystic kidney disease progresses to kidney failure faster in Hispanic patients than in those of other races or ethnicities, a study found.
Roxadustat reduced the need for rescue therapy among patients with any stage of chronic kidney disease.
Age was an important factor in the humoral response, regardless of chronic medical conditions.
Monitoring weight changes and intervening early in patients with CKD, especially those in advanced stages, are warranted, according to investigators.
In patients with cardiovascular disease, those with polyvascular disease are the most likely to progress to end-stage kidney disease, a study found.
Nearly 80% of patients in a recent study had very low serum zinc values, which raises concern for the advanced CKD population at large, according to investigators.
The study findings might indicate residual kidney function preservation in advanced CKD.
Registering Blacks on transplant wait list at eGFR of 24 to 25 mL/min/1.73 m2 could improve racial equity in wait time prior to ESKD onset